FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890904005> ?p ?o ?g. }

• W2890904005 endingPage "3013" @default.
• W2890904005 startingPage "3013" @default.
• W2890904005 abstract "3013 Background: IPI-549 is a potential first-in-class, oral, selective PI3K-γ inhibitor that in preclinical studies reprograms macrophages from an immune-suppressive to an immune-activating phenotype and can overcome resistance to checkpoint inhibitors. Methods: Ph 1/1b study IPI-549-01 (NCT02637531) is evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunomodulatory activity of IPI-549 to determine its recommended Ph 2 dose (RP2D) and preliminary efficacy, as monotherapy and combined with nivolumab (nivo), in advanced solid tumor pts. Pre- and on-treatment blood samples were obtained for flow cytometry, gene expression, and serum analysis. Results: Initial combination dose-escalation results are reported. 31 pts (30 evaluable), median age 57 yrs and median 4 prior therapies (8 with prior anti PD-(L)1 therapy), received IPI-549 20, 30, and 40 mg QD + nivo 240 mg Q2W in a 6+6 design. IPI-549 PK/PD were unaffected by nivo. The MTD was not reached. Most treatment-emergent adverse events (TEAEs) were Gr 1-2. The most common (≥ 2 pts) treatment-related TEAEs included rash (23%); pruritus (10%); and nausea, anemia, ALT increase, AST increase, and pyrexia (6% each), with no treatment-related deaths. 2 DLTs each occurred at IPI-549 30 mg (Gr 3 rash) and 40 mg QD (Gr 3 rash; Gr 3 ALT/AST increase). 2 pts demonstrated partial responses at first assessment (8 wks): 1 with adrenocortical carcinoma and 1 with microsatellite-stable gallbladder carcinoma receiving IPI-549 30 and 40 mg QD, respectively. 40% of pts (n = 12) remained on study ≥ 12 wks and 6 pts were ongoing at the 05 Feb data cutoff. Based on safety + PK/PD data, the RP2D was IPI-549 40 mg QD + nivo 240 mg Q2W. On-treatment blood samples show evidence of immune activation and reduced immune suppression, including upregulation of IFNg-responsive factors, such as PD-L1 and CXCL9/10, and dose-dependent re-invigoration/proliferation of exhausted PD1+CD8+CD45RA- T cells, evidenced by Ki67 increases. Conclusions: IPI-549 + nivo demonstrates favorable tolerability, early signs of clinical activity, and evidence of immune modulation. Combination expansion cohorts are enrolling at the RP2D. Clinical trial information: NCT02637531." @default.
• W2890904005 created "2018-09-27" @default.
• W2890904005 creator A5008479799 @default.
• W2890904005 creator A5011325668 @default.
• W2890904005 creator A5026095888 @default.
• W2890904005 creator A5026351607 @default.
• W2890904005 creator A5039301683 @default.
• W2890904005 creator A5042104226 @default.
• W2890904005 creator A5044582889 @default.
• W2890904005 creator A5045419282 @default.
• W2890904005 creator A5049612467 @default.
• W2890904005 creator A5054656505 @default.
• W2890904005 creator A5055056947 @default.
• W2890904005 creator A5060992997 @default.
• W2890904005 creator A5070570779 @default.
• W2890904005 creator A5071901078 @default.
• W2890904005 creator A5083345765 @default.
• W2890904005 creator A5083745558 @default.
• W2890904005 date "2018-05-20" @default.
• W2890904005 modified "2023-09-27" @default.
• W2890904005 title "Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors." @default.
• W2890904005 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.3013" @default.
• W2890904005 hasPublicationYear "2018" @default.
• W2890904005 type Work @default.
• W2890904005 sameAs 2890904005 @default.
• W2890904005 citedByCount "48" @default.
• W2890904005 countsByYear W28909040052018 @default.
• W2890904005 countsByYear W28909040052019 @default.
• W2890904005 countsByYear W28909040052020 @default.
• W2890904005 countsByYear W28909040052021 @default.
• W2890904005 countsByYear W28909040052022 @default.
• W2890904005 countsByYear W28909040052023 @default.
• W2890904005 crossrefType "journal-article" @default.
• W2890904005 hasAuthorship W2890904005A5008479799 @default.
• W2890904005 hasAuthorship W2890904005A5011325668 @default.
• W2890904005 hasAuthorship W2890904005A5026095888 @default.
• W2890904005 hasAuthorship W2890904005A5026351607 @default.
• W2890904005 hasAuthorship W2890904005A5039301683 @default.
• W2890904005 hasAuthorship W2890904005A5042104226 @default.
• W2890904005 hasAuthorship W2890904005A5044582889 @default.
• W2890904005 hasAuthorship W2890904005A5045419282 @default.
• W2890904005 hasAuthorship W2890904005A5049612467 @default.
• W2890904005 hasAuthorship W2890904005A5054656505 @default.
• W2890904005 hasAuthorship W2890904005A5055056947 @default.
• W2890904005 hasAuthorship W2890904005A5060992997 @default.
• W2890904005 hasAuthorship W2890904005A5070570779 @default.
• W2890904005 hasAuthorship W2890904005A5071901078 @default.
• W2890904005 hasAuthorship W2890904005A5083345765 @default.
• W2890904005 hasAuthorship W2890904005A5083745558 @default.
• W2890904005 hasConcept C111113717 @default.
• W2890904005 hasConcept C112705442 @default.
• W2890904005 hasConcept C121608353 @default.
• W2890904005 hasConcept C126322002 @default.
• W2890904005 hasConcept C143998085 @default.
• W2890904005 hasConcept C197934379 @default.
• W2890904005 hasConcept C2777472916 @default.
• W2890904005 hasConcept C2777701055 @default.
• W2890904005 hasConcept C2778375690 @default.
• W2890904005 hasConcept C2778570526 @default.
• W2890904005 hasConcept C2780030458 @default.
• W2890904005 hasConcept C2780580376 @default.
• W2890904005 hasConcept C71924100 @default.
• W2890904005 hasConcept C90924648 @default.
• W2890904005 hasConcept C98274493 @default.
• W2890904005 hasConceptScore W2890904005C111113717 @default.
• W2890904005 hasConceptScore W2890904005C112705442 @default.
• W2890904005 hasConceptScore W2890904005C121608353 @default.
• W2890904005 hasConceptScore W2890904005C126322002 @default.
• W2890904005 hasConceptScore W2890904005C143998085 @default.
• W2890904005 hasConceptScore W2890904005C197934379 @default.
• W2890904005 hasConceptScore W2890904005C2777472916 @default.
• W2890904005 hasConceptScore W2890904005C2777701055 @default.
• W2890904005 hasConceptScore W2890904005C2778375690 @default.
• W2890904005 hasConceptScore W2890904005C2778570526 @default.
• W2890904005 hasConceptScore W2890904005C2780030458 @default.
• W2890904005 hasConceptScore W2890904005C2780580376 @default.
• W2890904005 hasConceptScore W2890904005C71924100 @default.
• W2890904005 hasConceptScore W2890904005C90924648 @default.
• W2890904005 hasConceptScore W2890904005C98274493 @default.
• W2890904005 hasIssue "15_suppl" @default.
• W2890904005 hasLocation W28909040051 @default.
• W2890904005 hasOpenAccess W2890904005 @default.
• W2890904005 hasPrimaryLocation W28909040051 @default.
• W2890904005 hasRelatedWork W1934667138 @default.
• W2890904005 hasRelatedWork W2074207917 @default.
• W2890904005 hasRelatedWork W2088986153 @default.
• W2890904005 hasRelatedWork W2090169689 @default.
• W2890904005 hasRelatedWork W2538072326 @default.
• W2890904005 hasRelatedWork W2765994429 @default.
• W2890904005 hasRelatedWork W2966375918 @default.
• W2890904005 hasRelatedWork W2977436503 @default.
• W2890904005 hasRelatedWork W4251165208 @default.
• W2890904005 hasRelatedWork W4298086959 @default.
• W2890904005 hasVolume "36" @default.
• W2890904005 isParatext "false" @default.
• W2890904005 isRetracted "false" @default.
• W2890904005 magId "2890904005" @default.
• W2890904005 workType "article" @default.